RBCK1 and cardiac hypertrophy: Lovastatin prevented diastolic dysfunctions (Fig. 8A–C and Supplementary Table 6), exercise capacity and LW (Figs. 8D, E), cardiac hypertrophy and fibrosis (Fig. 8F and Supplementary Fig. 11) in HFpEF mice if infected with AAV9 expressing negative control shRNA, but not in HFpEF mice expressing circRNA-RBCK1 shRNA.